Industry News

11 December 2025

Novo Nordisk has completed its acquisition of Akero Therapeutics

Novo Nordisk and Akero Therapeutics Inc. announced that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed.

11 December 2025

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health

Zealand Pharma A/S, a biotechnology company transforming the future of metabolic health, today presents its strategy for redefining the near-term future of weight management and its vision to establish leadership in metabolic health at its Capital Markets Day in London.

10 December 2025

Amneal Receives USFDA approval for Albuterol Sulfate Inhalation Aerosol

Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Companys albuterol sulfate inhalation aerosol (90 mcg per actuation). The product is the generic equivalent of PROAIR® HFA (albuterol sulfate inhalation aerosol), a registered trademark of Teva Respiratory LLC.

4 December 2025

Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

Rentschler Biopharma, a leading global contract development and manufacturing organization for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.

4 December 2025

Celltrion announces USFDA approval of 300mg strength of OMLYCLO® (omalizumab-igec)

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg/2mL solution in a single-dose prefilled syringe for subcutaneous injection. In the U.S., OMLYCLO will be marketed and distributed exclusively by Celltrion USA, Inc.

3 December 2025

Sun Pharma introduces its global innovative drug, Ilumya® in India

Sun Pharmaceutical Industries Ltd. announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.

1 December 2025

Sandoz launches denosumab biosimilars in Europe

Sandoz the global leader in affordable medicines, today announced the European launch of Wyost® (denosumab 120 mg) and Jubbonti® (denosumab 60 mg).

1 December 2025

Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg

Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity.

22 November 2025

BE’s New 14-Valent Pneumococcal Vaccine Secures WHO Pre-Qualification

Biological E. Limited (BE), one of India’s leading vaccine and pharmaceutical manufacturers, has announced a major milestone with the World Health Organisation (WHO) granting Pre-qualification (PQ) status to its 14-valent Pneumococcal Conjugate Vaccine, PNEUBEVAX 14 (BE-PCV-14). This achievement marks the company’s 11th vaccine to enter the WHO PQ portfolio, strengthening its presence among global immunisation suppliers.

18 November 2025

AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India

AstraZeneca Pharma India Limited a leading science-led biopharmaceutical company and Sun Pharmaceutical Industries Limited today announced a second brand partnership for Sodium Zirconium Cyclosilicate in India.

Search

Novo Nordisk has completed its acquisition of Akero Therapeutics

RECOMMENDED POSTS

Recent content

Subscribe with us

Jobs by Category